AcelRx Pharmaceuticals, Inc. Appoints Raffi M. Asadorian as Chief Financial Officer, Effective August 16, 2017
July 19, 2017 at 07:01 am EDT
Share
AcelRx Pharmaceuticals, Inc. announced that Raffi M. Asadorian had been appointed by the company's Board of Directors to serve as Chief Financial Officer of the company, effective August 16, 2017. Before joining the company, Mr. Asadorian served as the Chief Financial Officer of Amyris, Inc. from January 2015 to January 2017, and as the Group Chief Financial Officer of Unilabs from August 2009 to October 2014.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
TALPHERA, INC. 
